Effect of GLP-1 and GIP on Insulin Secretion in Type-1 Diabetes Mellitus

Effect of GLP-1 and GIP on the Maximal Insulin Secretory Capacity in Type-1 Diabetes Mellitus

study hypothesis: treatment with GLP-1 and/or GIP is able to potentiate the maximal stimulated insulin secretion even in c-peptide negative type-1 diabetic patients classified as having no residual beta cell function left.

Inclusion Criteria:

• Age 18-60 years
• Type-1 diabetes diagnosed between 5-40 years of age
• Normal weight(BMI 18-27),
• Insulin treatment from time of diagnosis.

Exclusion Criteria:

• Severe complications to diabetes
• Abnormal liver or kidney function
• Haemoglobin below the lower limit
• Macroalbuminuria
• Systemic disease
• Pregnancy.